Skip to main content
. 2024 Jul 24;16(15):2636. doi: 10.3390/cancers16152636

Figure 1.

Figure 1

GHR antagonism in melanoma donor cells increased drug retention and decreased the IC50 of doxorubicin in recipient melanoma cells. A. Changes in the amounts of DiOC2(3) retained in the melanoma cells following administration with 20 μg/mL exosomes for 12-h, isolated from melanoma cells treated with 50 ng/mL GH independently or in combination with an IC50 dosage of doxorubicin and 500 nM pegvisomant. The fluorescent readouts from intracellular DiOC2(3) are presented for the Malme-3M (A), SK-MEL-28 (B), and SK-MEL-30 (C) melanoma cells. Three independent experiments were performed in triplicates and presented as the mean ± SD and p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). Changes in the IC50 values in Malme-3M (D), SK-MEL-28 (E), and SK-MEL-30 (F) melanoma cells following administration with the aforementioned exosomes and the increasing dosage of doxorubicin.